The BRAF oncogene is the most frequent genetic alteration in thyroid cancer (i.e., PTC) and is also detected in ATC, associated with poor clinical-pathological features of cancer such as extrathyroidal invasion, short time recurrence, and distant metastases [43, 44]. The gene discussed is BRAF; the disease is thyroid gland carcinoma.